Other Phase II trials are currently underway in patients with CD25+ Chronic Lymphocytic Leukemia (CLL), Cutaneous T cell lymphoma (CTCL) and Hairy Cell Leukemia (HCL). The gene discussed is IL2RA; the disease is B-cell chronic lymphocytic leukemia.